First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer

Uterine Cervical Neoplasms Clinical Trial

— CC-OV01  

Official title:

A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05393440
• Other study ID #: CC-OV01
• Status: Recruiting
• Phase: Phase 1
• Start date: September 16, 2022
• Est. completion date: July 1, 2024

Study information

• Verified date: April 2023
• Source: Zhongnan Hospital
• Contact: Shaoxing Sun, M. D.
• Phone: +08613871286154
• Email: sunshaoxing[@]whu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

Description:

This trial includes accelerated dose-escalation stage and dose-expansion stage. An engineered modification oncolytic viruses, BS-006, derived from type II herpes simplex virus strain are planed to be injected into the tumor every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. In dose-escalation stage, there are three dose levels (1 million, 10 millions, 100 millions 50 % cell culture infectious dose (CCID50)/ml) . Treatment dose will escalate to next higher level if no dose limiting toxicity happens for one time of injection in 3 subjects. Maximal tolerable dose is defined as the highest dose with no more than one dose limiting toxicity and is recommended for dose expansion stage. In dose-expansion stage, 15 subjects will be enrolled. BS-006 viruses will be injected into proper tumor lesions every 2 weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Radiology assessment will repeat every 6 weeks. Dose interruption, not reduction, is permitted in this stage.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: July 1, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Older than 18 years old and younger than 75 years old;

2. Zubrod-ECOG-WHO performance status is 0-1;

3. Life expectancy is longer than 3 months;

4. Pathologically proven malignant tumor originating from cervix uterine. All pathological types are acceptable except for sarcoma of any subtypes;

5. Radiological confirmed progression after at least 2 lines prior treatment or intolerable toxicity events occur during the second or later line treatment: 1) Neoadjuvant or adjuvant chemotherapy for no less than 2 cycles should be regarded as a separate treatment line if disease progress within 6 months after treatment finish;2) Regional treatment such as brachytherapy, radiofrequency ablation and artery embolization therapy should not be considered as a treatment line; 3) Treatment shift due to toxicity without radiological progression should not be counted as a separate line;

6. At least one measurement lesion according to RECIST 1.1;

7. At least one lesion with maximum diameter is larger than 1cm and surgically accessibility;

8. Patients must have recovered from prior treatment related toxicity to CTCAE grade 1 or 0;

9. Time interval to last systematic treatment or radiation affecting more than 20% bone marrow must be more than 4 weeks;

10. Time interval to last major surgery must be more than 4 weeks;

11. Abundant organ function: 1) Absolute neutrophil count is more than 1500/mm3 without granulocyte colony stimulating factor in the prior 7 days or long-acting granulocyte colony stimulating factor in the prior 20 days; platelets count is more than 100,000/mm3 without thrombopoietic drugs in the prior 7 days or platelet transfusion in the prior 10 days; hemoglobin is more than 9.0g/dL without red blood cell transfusion in the prior 20 days; 2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are lower than 2.5-fold upper limit of normal (ULN); serum bilirubin is lower than 1.5-fold ULN; serum albumin is more than 3g/dL; 3) Serum creatinine is lower than 1.5-fold ULN; 4) Prothrombin time and activated partial thromboplastin time is lower than 1.3-fold ULN;

12. Patients must have fully recovered from suspected or diagnosed genital herpes beyond 3 months;

13. Patients or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirement;

14. Women of childbearing potential must agree to use highly effective contraceptive methods in while on study drug and for at least 3 months after the last injection of BS-006. The pregnancy test within 7 days prior to the first injection must be negative.

Exclusion Criteria:

1. Cervical sarcoma of any subtype or prior history of other malignancy within 5 years;

2. Central nerve system metastasis;

3. Lesions met the requirement outlined in the inclusion criteria are unsafe for injection evaluated by investigators;

4. Severe comorbidities of any organs, including but not limit to myocardial infarction within 6 months, unstable angina pectoris, congestive heart failure, grade 3 or higher hypertension per CTCAE, cardiac arrhythmias, uncontrolled diabetes, fever of unknown reason, active digest ulcer and chronic obstructive pulmonary disease;

5. History of central nervous system infectious or demyelinating disease;

6. Severe infectious disease requiring constant antibiotic treatment;

7. Systematic glucocorticoids use within 2 weeks or glucocorticoids need for a long term;

8. Active infection of hepatitis B or C, HIV, cytomegalovirus, syphilis or other virus requiring treatment;

9. Immune disorder disease;

10. Antiviral treatment of any kinds;

11. Prior participant in experimental viral therapy;

12. Allergy to herpes simplex virus vaccine;

13. Participation in another research study within 4 weeks;

14. Poor compliance or incapacitated patients due to mental illness or other reasons;

15. Pregnancy or lactation.

Related Conditions & MeSH terms

• Uterine Cervical Neoplasms

Intervention

Biological:
• BS-006
BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.

Locations

Country	Name	City	State
China	Zhongnan Hospital of Wuhan University	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Zhongnan Hospital	Binhui Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

References & Publications (4)

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26. — View Citation

Kohlhapp FJ, Kaufman HL. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clin Cancer Res. 2016 Mar 1;22(5):1048-54. doi: 10.1158/1078-0432.CCR-15-2667. Epub 2015 Dec 30. — View Citation

Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402. doi: 10.1080/21645515.2020.1723363. Epub 2020 Feb 20. — View Citation

Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018 Dec 4;6(1):140. doi: 10.1186/s40425-018-0458-z. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal tolerable dose	The dose level at which there is no more than one DLT happens in dose-escalation stage	2 months after initiation of enrollment
Primary	Rate and grade of adverse events	The incidence of adverse events and severity graded according to CTCAE 5.0	From enrollment to 90 days after last treatment of all subjects
Primary	Cope numbers of BS-006	Detection of BS-006 virus copy numbers in urine, stool, saliva, blood and wiper of injection point and perineum	1 hours predose and 0.5 hours post-dose for first three doses and 1 hours predose ever after
Secondary	Tumor response rate	Tumor change assessed by investigator according to RECIST 1.1	Up to 2 years
Secondary	Abscopal effect rate	Rate of subjects who showed tumor shrinkage for any untreated lesion	Up to 2 years
Secondary	Progression free survival rate	Proportion of participants without tumor recurrence or death	Up to 2 years
Secondary	Overall survival rate	Proportion of survival participants	Up to 2 years